<DOC>
	<DOCNO>NCT01177800</DOCNO>
	<brief_summary>The purpose study determine superiority efficacy infliximab induction therapy chinese participant moderate severe plaque-type psoriasis ( scaly skin rash ) compare placebo ( inactive substance compare drug test whether drug real effect clinical trial ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Infliximab Chinese Participants With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , multicenter ( one hospital medical school team work medical research study ) placebo-controlled study infliximab participant moderate severe plaque-type psoriasis . All eligible participant randomly assign infliximab placebo group . The infliximab group receive 5 milligram per kilogram ( mg/kg ) infliximab infusion ( fluid medicine deliver vein way needle ) intravenously ( vein ) Week 0 , 2 6 induction treatment phase follow maintenance regimen intervention every 8 week 26 week . Placebo infusion also give Week 10 , 12 16 . The placebo group receive placebo infusion Week 0 , 2 , 6 , 14 22 . At Week 10 , participant placebo group receive infliximab induction therapy . Efficacy participant primarily evaluate percentage participant achieve Psoriasis Area Severity Index 75 ( PASI ) response Week 10 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>The body weight less equal 80 kilogram Participants diagnosis plaquetype psoriasis ( scaly skin rash ) great equal 6 month Screening ( participant concurrent psoriatic arthritis [ joint pain ] may enrol ) Participants plaquetype psoriasis cover great equal 10 percent total body surface area , Psoriasis Area Severity Index ( PASI ) score great equal 12 Screening Baseline Participants candidate systemic treatment psoriasis Females childbearing potential men must use adequate birth control measure agree use measure become pregnant ( carry unborn baby ) plan become pregnant 6 month receive last infusion study drug Participants nonplaque form psoriasis ( example , erythrodermic , guttate , pustular ) , current druginduced psoriasis ( example , new onset psoriasis exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) Participants pregnant , nurse plan become pregnant within one year enrol study Participants previous treatment infliximab Participants receive agent target reduce tumour necrosis factor biologic treatment within previous 3 month Participants use investigational drug within previous 4 week 5 time halflife investigational agent , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Remicade</keyword>
</DOC>